Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 302 followers
Latest posts
Last updated 14 minutes ago
Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages
14 minutes ago
Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening...
Chutes & Ladders—FDA rocked by leadership shake-ups
about 1 hour ago
As the Department of Health and Human Services grapples with the fallout...
Apollomics tags out of TYG oncology pact to cut costs, extend runway into 2026
about 2 hours ago
Apollomics has tagged out of its partnership with TYG Oncology, terminating an...
Shuren on FDA's future: 'Where do we go from here? ... Who knows?'
about 3 hours ago
In a webinar hosted by the medtech development service provider NAMSA, the...
Eli Lilly helps struggling Sangamo with $1.4B gene therapy deal
about 15 hours ago
Sangamo Therapeutics has secured a licensing deal with Eli Lilly that helps...
Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
about 20 hours ago
The California biotech will use the cash infusion to support its pipeline...
Unlocking Genomic Data: How NashBio is Advancing Innovation in Life Sciences
about 22 hours ago
NashBio is transforming life sciences by making complex genomic and real-world data...
Siemens AG to acquire lab R&D platform Dotmatics for $5.1B
about 22 hours ago
The German conglomerate said the deal would not only add to its...
Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks
about 24 hours ago
Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. An...
Aldeyra’s dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
about 24 hours ago
The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for...
BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs
1 day ago
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years...
Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics
1 day ago
Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate (ADC) space...